Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B‐cell lymphoma. A real‐world 112‐patient cohort - Université Paris-Est-Créteil-Val-de-Marne Access content directly
Journal Articles British Journal of Haematology Year : 2023

Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B‐cell lymphoma. A real‐world 112‐patient cohort

Enora Le Goff
Guillaume Gricourt
  • Function : Author
  • PersonId : 1309721
  • IdHAL : ggricourt

Abstract

Approximately 20%-50% of patients with large B-cell lymphoma (LBCL) experience poor outcomes. We aimed to evaluate the combined prognostic value of circulating tumour DNA (ctDNA) and total metabolic tumour volume (TMTV) in LBCL. This observational single-centre study included 112 newly diagnosed LBCL patients, receiving R-CHOP/R-CHOP-like chemotherapies. CtDNA load was calculated following next-generation sequencing of cell-free DNA (cfDNA) using a targeted 40-gene lymphopanel. TMTV was measured using a fully automated artificial intelligence-based method for lymphoma lesion segmentation. CtDNA was detected in cfDNA samples from 95 patients with a median concentration of 3.15 log haploid genome equivalents per mL. TMTV measurements were available for 102 patients. The median TMTV was 501 mL. High ctDNA load (>3.57 log hGE/mL) or high TMTV (>200 mL) were associated with shorter 1-year PFS (44% vs. 83%, p < 0.001 and 64% vs. 97%, p = 0.002, respectively). When combined, three prognostic groups were identified. The shortest PFS was observed when both TMTV and ctDNA load were high (p < 0.001). Even with a short follow up, combining ctDNA load with TMTV improved the risk stratification of patients with aggressive LBCL. In the near future, very high-risk patients could benefit from CAR T-cell therapy or bispecific antibodies as first-line treatments.
Fichier principal
Vignette du fichier
Br J Haematol - 2023 - Le Goff - Baseline circulating tumour DNA and total metabolic tumour volume as early outcome.pdf (3.72 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

hal-04134838 , version 1 (20-06-2023)

Identifiers

Cite

Enora Le Goff, Paul Blanc‐durand, Louise Roulin, Charlotte Lafont, Romain Loyaux, et al.. Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B‐cell lymphoma. A real‐world 112‐patient cohort. British Journal of Haematology, 2023, ⟨10.1111/bjh.18809⟩. ⟨hal-04134838⟩

Collections

INSERM IMRB UPEC
14 View
27 Download

Altmetric

Share

Gmail Facebook X LinkedIn More